{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T16:10:00Z","timestamp":1783786200342,"version":"3.55.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006398","name":"Roswell Park Alliance Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["P30CA16056"],"award-info":[{"award-number":["P30CA16056"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["R50CA283805"],"award-info":[{"award-number":["R50CA283805"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-25-1-0450"],"award-info":[{"award-number":["HT9425-25-1-0450"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-25-1-0449"],"award-info":[{"award-number":["HT9425-25-1-0449"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013401","name":"Ovarian Cancer Research Fund Alliance","doi-asserted-by":"publisher","award":["OCRA ECIG-2023-3-1005"],"award-info":[{"award-number":["OCRA ECIG-2023-3-1005"]}],"id":[{"id":"10.13039\/100013401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001320","name":"Roswell Park Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA283805"],"award-info":[{"award-number":["R50CA283805"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA16056"],"award-info":[{"award-number":["P30CA16056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["2P50CA159981-07A1"],"award-info":[{"award-number":["2P50CA159981-07A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ymthe.2025.09.047","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:43:24Z","timestamp":1759301004000},"page":"455-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer"],"prefix":"10.1016","volume":"34","author":[{"given":"Jessie L.","family":"Chiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nijamuddin","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Jacobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Gaulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lichty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer R.","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott I.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emese","family":"Zsiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7145-8444","authenticated-orcid":false,"given":"A.J. Robert","family":"McGray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.09.047_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2024.07.675","article-title":"Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial","volume":"189","author":"Gupta","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2020.10.014","article-title":"Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis","volume":"142","author":"Dafni","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib4","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s43018-023-00623-x","article-title":"A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer","volume":"4","author":"Bobisse","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007697","article-title":"Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer","volume":"11","author":"Verdegaal","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib7","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-023-02452-y","article-title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1\/2 trial interim results","volume":"29","author":"Hassan","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib8","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1111061","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","article-title":"Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation","volume":"22","author":"Kandalaft","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib11","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.hoc.2018.07.011","article-title":"Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer","volume":"32","author":"Chodon","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.ymthe.2025.09.047_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41416-019-0384-y","article-title":"Tumour-reactive T cell subsets in the microenvironment of ovarian cancer","volume":"120","author":"Westergaard","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113344","article-title":"Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma","volume":"12","author":"Gokuldass","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.09.047_bib16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006863","article-title":"BiTE secretion by adoptively transferred stem-like T cells improves FRalpha+ ovarian cancer control","volume":"11","author":"McGray","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib19","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib20","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-23-3841","article-title":"Mesothelin CAR T Cells Secreting Anti-FAP\/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma","volume":"30","author":"Wehrli","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.09.047_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/mt.2014.156","article-title":"Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells","volume":"23","author":"Iwahori","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.047_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7962","article-title":"Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo","volume":"16","author":"Diez-Alonso","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880108","article-title":"Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models","volume":"13","author":"Mu-Mosley","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd1524","article-title":"Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors","volume":"13","author":"Belmontes","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib25","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib26","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.09.047_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54565-8","article-title":"Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer","volume":"15","author":"Rosario","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.047_bib28","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1038\/s41467-018-07232-8","article-title":"Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas","volume":"9","author":"Rosario","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.047_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110298","article-title":"Roles of prostaglandins in immunosuppression","volume":"265","author":"Luo","year":"2024","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40425-019-0641-x","article-title":"Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer","volume":"7","author":"McGray","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib31","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.09.047_bib32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007444","article-title":"Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046\/TRU-D","volume":"11","author":"Park","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Na\u00efve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.09.047_bib35","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1158\/1078-0432.CCR-20-4740","article-title":"First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-\u03b1-Positive Advanced Solid Tumors","volume":"27","author":"Shimizu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.09.047_bib36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005968","article-title":"Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma","volume":"11","author":"Truxova","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymthe.2023.12.010","article-title":"Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8(+) T cell activity","volume":"32","author":"Luan","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.047_bib40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.omto.2023.02.002","article-title":"Reprogramming the tumor microenvironment leverages CD8(+) T cell responses to a shared tumor\/self antigen in ovarian cancer","volume":"28","author":"Mistarz","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2025.09.047_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092220","article-title":"Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy","volume":"14","author":"Schweer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.09.047_bib42","article-title":"New insights into the role of macrophages in cancer immunotherapy","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib43","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.09.047_bib44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","article-title":"Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion","volume":"58","author":"Waibl Polania","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.09.047_bib45","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.cmet.2023.07.006","article-title":"Emerging therapies in cancer metabolism","volume":"35","author":"Xiao","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.ymthe.2025.09.047_bib46","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1007\/s00262-021-02936-1","article-title":"A prime\/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer","volume":"70","author":"McGray","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2025.09.047_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158661","article-title":"Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression","volume":"132","author":"Colligan","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.09.047_bib48","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2025.09.047_bib49","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126853","article-title":"Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy","volume":"4","author":"Sun","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.09.047_bib51","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41591-025-03627-5","article-title":"Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial","volume":"31","author":"Lowery","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib53","article-title":"CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD-1 Blockade","volume":"12","author":"Zhou","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2025.09.047_bib54","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","article-title":"TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation","volume":"5","author":"Nutsch","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib55","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.09.047_bib56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-024-08076-7","article-title":"Differentiation fate of a stem-like CD4 T cell controls immunity to cancer","volume":"636","author":"Cardenas","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.09.047_bib57","article-title":"Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants","volume":"6","author":"Revach","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib58","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.09.047_bib59","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.09.047_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005177","article-title":"CD39 Expression Identifies Terminally Exhausted CD8+ T Cells","volume":"11","author":"Gupta","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ymthe.2025.09.047_bib61","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","article-title":"LAG3 associates with TCR\u2013CD3 complexes and suppresses signaling by driving co-receptor\u2013Lck dissociation","volume":"23","author":"Guy","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1465516","article-title":"Tertiary lymphoid structures in ovarian cancer","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib63","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.ccell.2024.09.007","article-title":"The activity of tertiary lymphoid structures in high grade serous ovarian cancer is governed by site, stroma, and cellular interactions","volume":"42","author":"MacFawn","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.09.047_bib64","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1038\/s41467-024-46873-w","article-title":"Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer","volume":"15","author":"Kasikova","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.047_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001136","article-title":"CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer","volume":"9","author":"Yang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1031746","article-title":"Tumor infiltrating CD8\/CD103\/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival","volume":"13","author":"Vlaming","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157215","article-title":"CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer","volume":"7","author":"Ukita","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.09.047_bib68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2025.09.047_bib69","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","article-title":"CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms","volume":"5","author":"Zhou","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib70","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.09.047_bib71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-019-0629-6","article-title":"Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer","volume":"7","author":"Liu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.09.047_bib72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.09.047_bib73","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study","volume":"14","author":"Gainor","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2025.09.047_bib74","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib75","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib76","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.09.047_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib78","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2172-10-44","article-title":"Bioluminescence-based visualization of CD4 T cell dynamics using a T lineage-specific luciferase transgenic model","volume":"10","author":"Chewning","year":"2009","journal-title":"BMC Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib80","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.09.047_bib81","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1089\/10430340050015590","article-title":"An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method","volume":"11","author":"Ng","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.09.047_bib82","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/mt.2013.255","article-title":"Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor","volume":"22","author":"McGray","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.09.047_bib83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib84","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data","volume":"8","author":"Wolock","year":"2019","journal-title":"Cell Syst."},{"key":"10.1016\/j.ymthe.2025.09.047_bib85","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13059-015-0844-5","article-title":"MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data","volume":"16","author":"Finak","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib86","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.09.047_bib87","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","article-title":"Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage","volume":"20","author":"Aran","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib88","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.cell.2018.05.061","article-title":"Recovering Gene Interactions from Single-Cell Data Using Data Diffusion","volume":"174","author":"van Dijk","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.09.047_bib89","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41592-024-02303-9","article-title":"CellRank 2: unified fate mapping in multiview single-cell data","volume":"21","author":"Weiler","year":"2024","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2025.09.047_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098679","article-title":"ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software","volume":"9","author":"Jacomy","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.09.047_bib91","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41587-019-0068-4","article-title":"Characterization of cell fate probabilities in single-cell data with Palantir","volume":"37","author":"Setty","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.09.047_bib92","doi-asserted-by":"crossref","DOI":"10.1063\/1.5064530","article-title":"Generalized Markov modeling of nonreversible molecular kinetics","volume":"150","author":"Reuter","year":"2019","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ymthe.2025.09.047_bib93","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics"},{"key":"10.1016\/j.ymthe.2025.09.047_bib94","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.09.047_bib95","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625008184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625008184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:35:01Z","timestamp":1783020901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625008184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1525001625008184"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.047","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.09.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}